Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)Clin. Breast Cancer 2022 Apr 01;22(3)269-278, DA Yardley, RR Young, KB Adelson, AL Silber, JE Najera, DB Daniel, N Peacock, L Finney, SJ Hoekstra, M Shastry, JD Hainsworth, HA Burris
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.